Novo Nordisk(US:NVO) Hu Xiu·2025-08-04 23:14Core Viewpoint - Novo Nordisk, once the "king of weight loss drugs," experienced its largest single-day stock drop of 30% at the end of July, marking a significant decline in market value, which previously exceeded Denmark's national GDP [1] Group 1: Market Dynamics - The weight loss drug market has become increasingly competitive, with Novo Nordisk facing challenges from its century-old rival, Eli Lilly, and price wars initiated by U.S. compound pharmacies [1] - The market is described as a "red sea," indicating intense competition and saturation among various players in the weight loss drug sector [1] Group 2: Company Performance - Despite being a leader in the weight loss drug market, Novo Nordisk is the first to face significant setbacks, raising questions about its strategies and market positioning [1] - The company has recently appointed a new CEO, who lacks direct experience in the highly competitive U.S. market, leading to uncertainty about the effectiveness of this leadership change in overcoming current challenges [1] Group 3: Financial Insights - The article suggests a review of the latest financial reports to understand the dynamics of the billion-dollar weight loss market and why the initial leader is struggling while competitors are gaining ground [1]